SEARCH

SEARCH BY CITATION

References

  • Arlin, Z., Case, Jr, D.C., Moore, J., Wiernik, P., Feldman, E., Saletan, S., Desai, P., Sia, L., Cartwright, K. & The Lederle Cooperative, G. (1990) Randomized multicenter trial of cytosine arabinoside with mitoxantrone or daunorubicin in previously untreated adult patients with acute nonlymphocytic leukemia (ANLL). Leukemia, 4, 177183.
  • Beksac, M., Arslan, O., Koc, H., Akan, H., Ilhan, O., Arat, M., Ozean, M., Gurman, G., Konuk, N. & Uysal, A. (1998) Randomised unicenter trial for comparison of three regimens in de novo adult acute nonlymphoblastic leukaemia. Medical Oncology, 15, 183190.
  • Berman, E., Heller, G., Santorsa, J.A., McKenzie, S., Gee, T., Kempin, S., Gulati, S., Andreeff, M., Kolitz, J., Gabrilove, J., Reich, L., Mayer, K., Keefe, D., Trainor, K., Schluger, A., Penenberg, D., Raymond, V., O'Reilly, R., Jhanwar, S., Young, C. & Clarkson, B. (1991) Results of a randomized trial comparing idarubicin and cytosine arabinoside with daunorubicin and cytosine arabinoside in adult patients with newly diagnosed acute myelogenous leukemia. Blood, 77, 16661674.
  • Berman, E., Wiernik, P., Vogler, R., Velez-Garcia, E., Bartolucci, A. & Whaley, F.S. (1997) Long-term follow-up of three randomized trials comparing idarubicin and daunorubicin as induction therapies for patients with untreated acute myeloid leukemia. Cancer, 80, 21812185.
  • Bonnet, D. & Dick, J.E. (1997) Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nature Medicine, 3, 730737.
  • Borenstein, M., Hedges, V.H., Higgins, J.P.T. & Rothstein, H.R. (2009) Introduction to Meta-Analysis. Wiley, West Sussex, United Kingdom.
  • Burnett, A.K., Hills, R.K., Milligan, D.W., Goldstone, A.H., Prentice, A.G., McMullin, M.-F., Duncombe, A., Gibson, B. & Wheatley, K. (2010) Attempts to optimize induction and consolidation treatment in acute myeloid leukemia: results of the MRC AML12 trial. Journal of Clinical Oncology, 28, 586595.
  • Children's Oncology Group. (2008) Long-Term Follow-Up Guidelines for Survivors of Childhood, Adolescent, and Young Adult Cancers, Version 3.0. Children's Oncology Group, Arcadia, CA.
  • Creutzig, U., Ritter, J., Zimmermann, M., Hermann, J., Gadner, H., Sawatzki, D.B., Niemeyer, C.M., Schwabe, D., Selle, B., Boos, J., Kuhl, J. & Feldges, A. (2001) Idarubicin improves blast cell clearance during induction therapy in children with AML: results of study AML-BFM 93. Leukemia, 15, 348354.
  • Creutzig, U., Zimmermann, M., Dworzak, M., Bourquin, J.-P., Neuhoff, C., Sander, A., Stary, J. & Reinhardt, D. (2010) Study AML-BFM 2004: improved survival in childhood acute myeloid leukemia without increased toxicity. Blood (ASH Annual Meeting Abstracts), 116, 181.
  • van Dalen, E.C., Caron, H.N., Dickinson, H.O. & Kremer, L.C. (2011) Cardioprotective interventions for cancer patients receiving anthracyclines. Cochrane Database Systematic Review, 15, CD003917.
  • De Moerloose, B., Suciu, S., Munzer, M., Piette, C., Yakouben, K., Margueritte, G., Lutz, P., Uyttebroeck, A., Rohrlich, P., Ferster, A., Boutard, P., Dresse, M.F., Rialland, X., Norton, L., Sirvent, N., Karrasch, M., Benoit, Y. & Bertrand, Y. (2011) Similar efficacy and toxicity profile for idarubicine and mitoxantrone in induction and intensification treatment of children with Acute Myeloid Leukemia (AML) or Myelodysplasia (MDS): long-term results of the EORTC-CLG randomized phase III trial 58921. Blood, 118, 11221123.
  • Eridani, S., Singh, A.K., Slater, N.G.P., Pearson, T.C., Phaure, T.A.J., Semple, M.J., Erskine, J.G., Toolis, F. & Birch, A.D.J. (1989) A phase II study of idarubicin versus daunorubicin in the treatment of acute non-lymphocytic leukaemia. Cancer Journal, 2, 296298.
  • Fernandez, H.F., Sun, Z., Yao, X., Litzow, M.R., Luger, S.M., Paietta, E.M., Racevskis, J., Dewald, G.W., Ketterling, R.P., Bennett, J.M., Rowe, J.M., Lazarus, H.M. & Tallman, M.S. (2009) Anthracycline dose intensification in acute myeloid leukemia. New England Journal of Medicine, 361, 12491259.
  • Gibson, B.E.S., Webb, D.K.H., Howman, A.J., de Graaf, S.S.N., Harrison, C.J. & Wheatley, K. (2011) Results of a randomized trial in children with acute myeloid leukaemia: medical research council AML12 trial. British Journal of Haematology, 155, 366376.
  • Harousseau, J.L., Pignon, B., Witz, F., Polin, V., Tellier, Z., Hurteloup, P. & Cahn, J.Y. (1996) Treatment of acute myeloblastic leukemia in adults. The GOELAM experience. Hematology and Cell Therapy, 38, 381391.
  • Higgins, J. & Green, S. (2008) Cochrane Handbook for Systematic Reviews of Interventions. Wiley-Blackwell, ????.
  • Hijiya, N., Ness, K.K., Ribeiro, R.C. & Hudson, M.M. (2009) Acute leukemia as a secondary malignancy in children and adolescents: current findings and issues. Cancer, 115, 2335.
  • Intragumtornchai, T., Lekhakula, A., Ohamaprasit, T. & Sutcharitchan, P. (1999) Idarubicin versus doxorrubicin in combination with cytarabine as first course induction therapy in acute myelogenous leukemia: a randomized controlled trial. Asian Pacific Journal of Allergy and Immunology, 17(suppl. I), 23.
  • Koc, Y., Oyan, B., Kars, A., Tekuzman, G., Canpinar, H. & Kansu, E. (2004) A randomized trial of continuous infusion versus bolus mitoxantrone in combination with cytarabine in newly diagnosed patients with acute myeloblastic leukemia. Hematological Oncology, 22, 4353.
  • Landis, J.R. & Koch, G.G. (1977) The measurement of observer agreement for categorical data. Biometrics, 33, 159174.
  • Lee, J.-H., Joo, Y.-D., Kim, H., Bae, S.H., Kim, M.K., Zang, D.Y., Lee, J.-L., Lee, G.W., Lee, J.-H., Park, J.-H., Kim, D.-Y., Lee, W.-S., Ryoo, H.M., Hyun, M.S., Kim, H.J., Min, Y.J., Jang, Y.-E., Lee, K.-H. & Cooperative Study Group, A.f.H. (2011) A randomized trial comparing standard versus high-dose daunorubicin induction in patients with acute myeloid leukemia. Blood, 118, 38323841.
  • Lowenberg, B., Ossenkoppele, G.J., van Putten, W., Schouten, H.C., Graux, C., Ferrant, A., Sonneveld, P., Maertens, J., Jongen-Lavrencic, M., von Lilienfeld-Toal, M., Biemond, B.J., Vellenga, E., van Marwijk Kooy, M., Verdonck, L.F., Beck, J., Dohner, H., Gratwohl, A., Pabst, T. & Verhoef, G. (2009) High-dose daunorubicin in older patients with acute myeloid leukemia. New England Journal of Medicine, 361, 12351248.
  • Mandelli, F., Vignetti, M., Suciu, S., Stasi, R., Petti, M.-C., Meloni, G., Muus, P., Marmont, F., Marie, J.-P., Labar, B., Thomas, X., Di Raimondo, F., Willemze, R., Liso, V., Ferrara, F., Baila, L., Fazi, P., Zittoun, R., Amadori, S. & de Witte, T. (2009) Daunorubicin versus mitoxantrone versus idarubicin as induction and consolidation chemotherapy for adults with acute myeloid leukemia: the EORTC and GIMEMA Groups Study AML-10.[Erratum appears in J Clin Oncol. 2010 Mar 10;28(8):1438]. Journal of Clinical Oncology, 27, 53975403.
  • Masaoka, T., Ogawa, M., Yamada, K., Kimura, K. & Ohashi, Y. (1996) A phase II comparative study of idarubicin plus cytarabine versus daunorubicin plus cytarabine in adult acute myeloid leukemia. Seminars in Hematology, 33, 1217.
  • Moher, D., Liberati, A., Tetzlaff, J. & Altman, D.G. (2009) Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. BMJ, 339, b2535.
  • Morrison, F.S., Kopecky, K.J., Head, D.R., Athens, J.W., Balcerzak, S.P., Gumbart, C., Dabich, L., Costanzi, J.J., Coltman, C.A., Saiki, J.H., Hussein, K.K., Fabian, C.J. & Appelbaum, F.R. (1992) Late intensification with POMP chemotherapy prolongs survival in acute myelogenous leukemia–Results of a Southwest Oncology Group study of rubidazone versus adriamycin for remission induction, prophylactic intrathecal therapy, late intensification, and levamisole maintenance. Leukemia, 6, 708714.
  • Nagura, E., Kimura, K., Yamada, K., Ohta, K., Maekawa, T., Takaku, F., Uchino, H., Masaoka, T., Amaki, I., Kawashma, K., Kariyone, S., Toyama, K., Ichimaru, M., Nomura, T., Sakai, Y., Takatsuki, K. & Hamajima, N. (1994) Nationwide randomized comparative study of daunorubicin and aclarubicin in combination with behenoyl cytosine arabinoside, 6-mercaptopurine, and prednisolone for previously untreated acute myeloid leukemia. Cancer Chemotherapy and Pharmacology, 34, 2329.
  • National Cancer Institute. (2012) Adult Acute Myeloid Leukemia Treatment (PDQ); available on-line: http://www.cancer.gov/cancertopics/pdq/treatment/adultAML/healthprofessional.
  • Nikanfar, A., Asvadi, I. & Vaez, J. (2007) Mitoxantrone plus cytarabine versus daunorubicin plus cytarabine as induction therapy for previously untreated adult patients with acute myeloid leukemia. Pakistan Journal of Medical Sciences, 23, 909912.
  • de Nully Brown, P., Hoffmann, T., Hansen, O.P., Boesen, A.M., Gronbaek, K., Hippe, E., Jensen, M.K., Thorling, K., Storm, H.H. & Pedersen-Bjergaard, J. (1997) Long-term survival and development of secondary malignancies in patients with acute myeloid leukemia treated with aclarubicin or daunorubicin plus cytosine arabinoside followed by intensive consolidation chemotherapy in a Danish national phase III trial. Danish Society of Haematology Study Group on AML. Leukemia, 11, 3741.
  • Ohtake, S., Miyawaki, S., Fujita, H., Kiyoi, H., Shinagawa, K., Usui, N., Okumura, H., Miyamura, K., Nakaseko, C., Miyazaki, Y., Fujieda, A., Nagai, T., Yamane, T., Taniwaki, M., Takahashi, M., Yagasaki, F., Kimura, Y., Asou, N., Sakamaki, H., Handa, H., Honda, S., Ohnishi, K., Naoe, T. & Ohno, R. (2011) Randomized study of induction therapy comparing standard-dose idarubicin with high-dose daunorubicin in adult patients with previously untreated acute myeloid leukemia: the JALSG AML201 Study. Blood, 117, 23582365.
  • van der Pal, H.J., van Dalen, E.C., van Delden, E., van Dijk, I.W., Kok, W.E., Geskus, R.B., Sieswerda, E., Oldenburger, F., Koning, C.C., van Leeuwen, F.E., Caron, H.N. & Kremer, L.C. (2012) High risk of symptomatic cardiac events in childhood cancer survivors. Journal of Clinical Oncology, 30, 14291437.
  • Paul, C., Bjorkholm, M. & Christenson, I. (1981) Comparison of duanorubicin and daunorubicin-DNA complex in the treatment of acute nonlymphoblastic leukemia. Cancer Chemotherapy and Pharmacology, 6, 6573.
  • Paul, C., Tidefelt, U., Gahrton, G., Bjorkholm, M., Jarnmark, M., Killander, A., Kimby, E., Liliemark, J., Lindeberg, A., Lindquist, R., Lockner, D., Lonnqvist, B., Mellstedt, H., Merk, K., Palmblad, J., Peterson, C., Simonsson, B., Stalfelt, A.M. & Sundstrom, C. (1991) A randomized comparison of doxorubicin and doxorubicin-DNA in the treatment of acute nonlymphoblastic leukemia. Leukemia and Lymphoma, 3, 355364.
  • Pavlovsky, S., Gonzalez Llaven, J., Garcia Martinez, M.A., Sobrevilla, P., Eppinger-Helft, M., Marin, A., Lopez-Hernandez, M., Fernandez, I., Rubio, M.E., Ibarra, S., Lluesma, M., Ruiz Arguelles, G., Jose de Diego, F., Corrado, C., Milone, G. & Lopez, A.M. (1994) A randomized study of mitoxantrone plus cytarabine versus daunomycin plus cytarabine in the treatment of previously untreated adult patients with acute nonlymphocytic leukemia. Annals of Hematology, 69, 1115.
  • Pignon, B., Witz, F., Desablens, B., Leprise, P.Y., Francois, S., Linassier, C., Berthou, C., Caillot, D., Lioure, B., Cahn, J.Y., Casassus, P., Sadoun, A., Audhuy, B., Guyotat, D., Briere, J., Vilque, J.P., Baranger, L., Polin, V., Berthaud, P., Hurteloup, P., Herve, P. & Harousseau, J.L. (1996) Treatment of acute myelogenous leukaemia in patients aged 50–65: idarubicin is more effective than zorubicin for remission induction and prolonged disease-free survival can be obtained using a unique consolidation course. British Journal of Haematology, 94, 333341.
  • Pui, C.-H. (2006) Childhood Leukamias. Cambridge University Press, Cambridge, United Kingdom.
  • Pulte, D., Gondos, A. & Brenner, H. (2009) Trends in survival after diagnosis with hematologic malignancy in adolescence or young adulthood in the United States, 1981–2005. Cancer, 115, 49734979.
  • Sutton, A.J., Duval, S.J. & Tweedie, R.L. (2000) Empirical assessment of effect of publication bias on meta-analyses. BMJ, 157, 41577.
  • Takemoto, Y. & Ogawa, M. (1998) A prospective randomized trial comparing KRN8602(MX2) and cytarabine (AraC) versus daunorubicin(DNR) and AraC in adult patients with newly diagnosed acute myelogenous leukemia (AML). American Society of Clinical Oncology (ASCO) Annual Meeting Abstracts, Vol. 17, Abstract 151.
  • Vogler, W.R., Velez-Garcia, E., Weiner, R.S., Floum, M.A., Bartolucci, A.A., Omura, G.A., Gerber, M.C. & Banks, P.L.C. (1992) A phase III trial comparing idarubicin and daunorubicin in combination with cytarabine in acute myelogenous leukemia: a Southeastern Cancer Study Group study. Journal of Clinical Oncology, 10, 11031111.
  • Wahlin, A., Hornsten, P., Hedenus, M. & Malm, C. (1991) Mitoxantrone and cytarabine versus daunorubicin and cytarabine in previously untreated patients with acute myeloid leukemia. Cancer Chemotherapy and Pharmacology, 28, 480483.
  • Wheatley, K. (1998) A systematic collaborative overview of randomized trials comparing idarubicin with daunorubicin (or other anthracyclines) as induction therapy for acute myeloid leukaemia. British Journal of Haematology, 103, 100109.
  • Wiernik, P.H., Banks, P.L.C., Case, Jr, D.C., Arlin, Z.A., Periman, P.O., Todd, M.B., Ritch, P.S., Enck, R.E. & Weitberg, A.B. (1992) Cytarabine plus idarubicin or daunorubicin as induction and consolidation therapy for previously untreated adult patients with acute myeloid leukemia. Blood, 79, 313319.
  • Yates, J., Glidewell, O., Wiernik, P., Cooper, M.R., Steinberg, D., Dosik, H., Levy, R., Hoagland, C., Henry, P., Gottlieb, A., Cornell, C., Berenberg, J., Hutchison, J.L., Raich, P., Nissen, N., Ellison, R.R., Frelick, R., James, G.W., Falkson, G., Silver, R.T., Haurani, F., Green, M., Henderson, E., Leone, L. & Holland, J.F. (1982) Cytosine arabinoside with daunorubicin or adriamycin for therapy of acute myelocytic leukemia: a CALGB study. Blood, 60, 454462.
  • Ziogas, D.C., Voulgarelis, M. & Zintzaras, E. (2011) A network meta-analysis of randomized controlled trials of induction treatments in acute myeloid leukemia in the elderly. Clinical Therapeutics, 33, 254279.